Technical Analysis for CTIC - Cell Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 1.17 -5.65% -0.07
CTIC closed down 5.65 percent on Friday, February 21, 2020, on 43 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical CTIC trend table...

Date Alert Name Type % Chg
Stochastic Reached Oversold Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish -5.65%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -5.65%
20 DMA Resistance Bearish -6.40%
MACD Bearish Centerline Cross Bearish -6.40%
Outside Day Range Expansion -6.40%
20 DMA Resistance Bearish -9.30%
MACD Bearish Signal Line Cross Bearish -9.30%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Cell Therapeutics, Inc. engages in the acquisition, development, and commercialization of treatments for cancer. The company primary focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative, which is in Phase III clinical trials for the treatment of multiply relapsed or refractory aggressive non-Hodgkin lymphoma. It is also developing Opaxio, a chemotherapeutic agent that is in Phase III clinical trials for the treatment of ovarian cancer; in Phase II clinical trials for the treatment of malignant brain cancer; and in Phase I-II clinical trials for the treatment of head and neck cancer. In addition, the company is developing Pacritinib, a Janus kinase 2 inhibitor that is in Phase III clinical trials for the treatment of myelofibrosis; Tosedostat, an aminopeptidase inhibitor that is in Phase I-II clinical trials for the treatment of acute myeloid leukemia; and Brostallicin, which is in Phase II clinical trials for the treatment of triple-negative breast cancer. It has a license and co-development agreement with Chroma Therapeutics, Ltd. to develop and commercialize Tosedostat. Cell Therapeutics, Inc. was founded in 1991 and is headquartered in Seattle, Washington.
Cancer Chemical Compounds Organic Compounds Cancer Treatments Acute Myeloid Leukemia Ovarian Cancer Antibody Drug Conjugates Seattle Genetics Ethers Head And Neck Cancer Pyrrolidines Treatment Of Acute Myeloid Leukemia Treatment Of Ovarian Cancer Camidanlumab Tesirine Myelofibrosis Triple Negative Breast Cancer Pacritinib Pixantrone Treatment Of Head And Neck Cancer

Is CTIC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 1.93
52 Week Low 0.6305
Average Volume 542,637
200-Day Moving Average 0.94
50-Day Moving Average 1.36
20-Day Moving Average 1.28
10-Day Moving Average 1.30
Average True Range 0.09
ADX 13.49
+DI 20.12
-DI 25.72
Chandelier Exit (Long, 3 ATRs ) 1.17
Chandelier Exit (Short, 3 ATRs ) 1.43
Upper Bollinger Band 1.42
Lower Bollinger Band 1.15
Percent B (%b) 0.08
BandWidth 20.86
MACD Line -0.02
MACD Signal Line 0.00
MACD Histogram -0.0147
Fundamentals Value
Market Cap 37.12 Million
Num Shares 31.7 Million
EPS -1.88
Price-to-Earnings (P/E) Ratio -0.62
Price-to-Sales 2.78
Price-to-Book 2.33
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.31
Resistance 3 (R3) 1.31 1.28 1.28
Resistance 2 (R2) 1.28 1.24 1.27 1.27
Resistance 1 (R1) 1.22 1.22 1.21 1.22 1.27
Pivot Point 1.19 1.19 1.18 1.18 1.19
Support 1 (S1) 1.13 1.15 1.12 1.13 1.07
Support 2 (S2) 1.10 1.13 1.09 1.07
Support 3 (S3) 1.04 1.10 1.06
Support 4 (S4) 1.04